840 Memorial Drive
Entrance on Blackstone Street, Third Floor
About AxcellaAxcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass.
CEO: Robert Connelly
CMO: Christopher I. Wright
CFO: Thomas Leggett
Please click here for Axcella job opportunities.
87 articles with Axcella
Dr. Mitchener brings 15 years of pharmaceutical industry experience driving domestic and international commercialization, BD&L, operations, and value creation to Axcella.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
Mr. Hinshaw is a highly accomplished health care executive with nearly three decades of global pharmaceutical experience and was most recently Executive Vice President and Head of U.S. Oncology at Novartis.
Axcella Announces The Appointment Of Ivana Magovcevic-Liebisch, Ph.D., J.D., As Executive Vice President, Chief Strategy And Corporate Development Officer